, including CpG island methylation status. 41 , 64 Future dissection of molecular subsets within these categories will likely lead to further refinement of recommendations on risk assessment and adjuvant therapy, in patients with stage II colon cancers in
Search Results
Biomarker Use in Colorectal Cancer Therapy
Robin K. Kelley, Grace Wang, and Alan P. Venook
Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide
Kelly G. Paulson and Shailender Bhatia
trials are underway to test the safety and efficacy of ICIs as systemic adjuvant therapy in high-risk patients with MCC. A multicenter, randomized, placebo-controlled phase III trial investigating adjuvant avelumab in patients with clinically detected
Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer
Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow
examination. This allows for an accurate diagnosis, identification of disease extent, prognostic assessment, and selection of patients for adjuvant therapy. The advantage of surgical-pathologic staging over clinical staging was reported in the GOG 33 trial
Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer
Pranav Murthy, Mazen S. Zenati, Samer S. AlMasri, Annissa DeSilva, Aatur D. Singhi, Alessandro Paniccia, Kenneth K. Lee, Richard L. Simmons, Nathan Bahary, Michael T. Lotze, and Amer H. Zureikat
adjuvant therapy, and total number of chemotherapy cycles. All tests used in the analysis were 2-sided, with an alpha of .05 indicating statistical significance. All statistical analyses were performed using Stata 14.2 (StataCorp LP). Results
Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™
National Comprehensive Cancer Network or the NCCN Foundation. AB2013-21. Impact of Age on the Efficacy of Newer Adjuvant Therapies in More Than 14,500 Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database Nadine J. McCleary, Jeffrey
Patterns of Chemotherapy Administration in High-Risk Soft Tissue Sarcoma and Impact on Overall Survival
Sujana Movva, Margaret von Mehren, Eric A. Ross, and Elizabeth Handorf
Frustaci S De Paoli A Bidoli E . Ifosfamide in the adjuvant therapy of soft tissue sarcomas . Oncology 2003 ; 65 ( Suppl 2 ): 80 – 84 . 17 Canter RJ Qin LX Maki RG . A synovial sarcoma-specific preoperative nomogram supports a survival
Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
Virginia G. Kaklamani and William J. Gradishar
an additional 12 weeks, followed by definitive surgery. After surgery, patients received adjuvant therapy along with the same anti-HER2 therapy as assigned preoperatively, for a total of 52 weeks of anti-HER2 therapy. The primary end point of the
Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma
Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan
. She was seen by Medical Oncology and underwent 8 cycles of adjuvant chemotherapy with single-agent gemcitabine. Six months after completion of adjuvant therapy, she was found to have peritoneal lesions concerning for recurrent metastatic disease on
Prostate Cancer, Version 1.2014
James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho
to: Describe the current standard of care for the management of patients with prostate cancer Discuss the role of adjuvant therapy in the management of prostate cancer NCCN Categories of Evidence and Consensus Category 1: Based upon high
Survivorship: Pain Version 1.2014
Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass
breast surgery and 50% in those treated with lung surgery. 1 Arthralgias, characterized by joint pain and stiffness, occur in roughly half of women taking aromatase inhibitors as adjuvant therapy for breast cancer. 15 Pelvic pain often occurs after
